JP6014596B2 - 均一コンジュゲーションのための抗体足場 - Google Patents

均一コンジュゲーションのための抗体足場 Download PDF

Info

Publication number
JP6014596B2
JP6014596B2 JP2013538829A JP2013538829A JP6014596B2 JP 6014596 B2 JP6014596 B2 JP 6014596B2 JP 2013538829 A JP2013538829 A JP 2013538829A JP 2013538829 A JP2013538829 A JP 2013538829A JP 6014596 B2 JP6014596 B2 JP 6014596B2
Authority
JP
Japan
Prior art keywords
antibody
antibodies
cysteine
amino acid
interchain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013538829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014505463A5 (enExample
JP2014505463A (ja
Inventor
ディマージ，ナッツァレノ
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2014505463A publication Critical patent/JP2014505463A/ja
Publication of JP2014505463A5 publication Critical patent/JP2014505463A5/ja
Application granted granted Critical
Publication of JP6014596B2 publication Critical patent/JP6014596B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013538829A 2010-11-09 2011-11-08 均一コンジュゲーションのための抗体足場 Expired - Fee Related JP6014596B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41158810P 2010-11-09 2010-11-09
US61/411,588 2010-11-09
PCT/US2011/059775 WO2012064733A2 (en) 2010-11-09 2011-11-08 Antibody scaffold for homogenous conjugation

Publications (3)

Publication Number Publication Date
JP2014505463A JP2014505463A (ja) 2014-03-06
JP2014505463A5 JP2014505463A5 (enExample) 2014-12-25
JP6014596B2 true JP6014596B2 (ja) 2016-10-25

Family

ID=46051511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013538829A Expired - Fee Related JP6014596B2 (ja) 2010-11-09 2011-11-08 均一コンジュゲーションのための抗体足場

Country Status (4)

Country Link
US (2) US20130330350A1 (enExample)
EP (1) EP2638066A4 (enExample)
JP (1) JP6014596B2 (enExample)
WO (1) WO2012064733A2 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
RS57827B1 (sr) 2012-02-15 2018-12-31 Novo Nordisk As Antitela koja vezuju protein 1 prepoznavanja peptidoglikana
JP6411218B2 (ja) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー／エス 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9700638B2 (en) 2012-05-08 2017-07-11 Rutgers, The State University Of New Jersey Near infrared label and methods of use thereof
WO2014182927A1 (en) * 2013-05-08 2014-11-13 Rutgers, The State University Of New Jersey Near infrared label and methods of use thereof
EA201591465A1 (ru) * 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
BR112015025549A2 (pt) * 2013-04-07 2017-10-10 Bioex Therapeutics Inc anticorpo contra o receptor do fator de crescimento epidérmico
DK2991683T3 (da) 2013-05-02 2019-11-04 Glykos Finland Oy Konjugater af et glykoprotein eller en glykan med en toksisk ladning
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
AU2014346792A1 (en) 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
KR20160097336A (ko) 2013-12-12 2016-08-17 스템센트알엑스 인코포레이티드 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
MX2016010295A (es) * 2014-02-11 2016-10-17 Seattle Genetics Inc Reduccion selectiva de proteinas.
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
TWI871999B (zh) * 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
US12685781B2 (en) 2014-04-10 2026-07-21 Daiichi Sankyo Company, Limited Anti-HER3 antibody-drug conjugate
CN106536559B (zh) 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US20160251417A1 (en) * 2015-01-22 2016-09-01 Prothena Biosciences Limited Antibodies recognizing medin
GB201506399D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506407D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506389D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506394D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506393D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JPWO2018110515A1 (ja) 2016-12-12 2019-10-24 第一三共株式会社 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
SG11201906554RA (en) 2017-01-17 2019-08-27 Daiichi Sankyo Co Ltd Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
MX2019009372A (es) * 2017-02-08 2019-12-11 Pfizer Produccion a gran escala para cisteinas de anticuerpo protegidas y no protegidas y su uso en la conjugacion de proteinas terapeuticas.
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
US12667557B2 (en) 2017-02-28 2026-06-30 Daiichi Sankyo Company, Limited Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate
SMT202200490T1 (it) 2017-04-18 2023-01-13 Medimmune Ltd Coniugati di pirrolobenzodiazepina
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體－藥物結合物之製造方法
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
EP3677589B1 (en) 2017-08-31 2025-11-26 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
ES2920123T3 (es) 2017-11-14 2022-08-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
CN108642176B (zh) * 2018-04-12 2021-11-09 江门市中心医院 Part1作为乳腺癌诊断、治疗以及预后标志物的应用
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3794042B1 (en) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate
US20210283141A1 (en) * 2018-05-25 2021-09-16 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3831853A4 (en) 2018-07-27 2022-06-01 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT
IL325918A (en) 2018-07-31 2026-03-01 Daiichi Sankyo Co Ltd Antibody-drug conjugates for use in the treatment of metastatic brain tumor
WO2020059772A1 (ja) 2018-09-20 2020-03-26 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN110596387B (zh) * 2019-09-20 2020-06-12 四川大学华西医院 Cox10自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
US20230241259A1 (en) * 2020-06-10 2023-08-03 Memorial Sloan Kettering Cancer Center IMAGING COMPOUNDS SELECTIVE FOR NaV1.7
WO2022104692A1 (en) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Engineered antibody, antibody-drug conjugate, and use thereof
GB202105186D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CN117285647A (zh) * 2022-06-17 2023-12-26 南京北恒生物科技有限公司 靶向ccr8的嵌合抗原受体及其用途
JPWO2024248123A1 (enExample) 2023-06-02 2024-12-05
WO2026098621A1 (zh) * 2024-11-08 2026-05-15 百力司康生物医药(杭州)有限公司 工程改造的定点偶联抗体、抗体偶联药物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0604580A1 (en) * 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
TR201808537T4 (tr) * 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US20080305044A1 (en) * 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
EP2615175B1 (en) * 2007-05-31 2018-08-08 Genmab A/S Monovalent human antibodies
KR20100107501A (ko) * 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체

Also Published As

Publication number Publication date
US20170183408A1 (en) 2017-06-29
WO2012064733A2 (en) 2012-05-18
JP2014505463A (ja) 2014-03-06
EP2638066A2 (en) 2013-09-18
US20130330350A1 (en) 2013-12-12
EP2638066A4 (en) 2015-06-03
WO2012064733A3 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
JP7165175B2 (ja) 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
US20170183408A1 (en) Antibody scaffold for homogenous conjugation
US20210069341A1 (en) Conjugated compounds comprising cysteine-engineered antibodies
JP5918129B2 (ja) 部位特異的共役のための操作されたＦｃ領域
US20200069764A1 (en) Antibodies and antibody fragments for site-specific conjugation
KR102668727B1 (ko) 다중특이적 항원-결합 단백질
AU2015205870A1 (en) ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
HK1196090A (en) Engineered fc regions for site-specific conjugation
HK1234418B (en) Conjugated compounds comprising cysteine-engineered antibodies
HK1234418A1 (en) Conjugated compounds comprising cysteine-engineered antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160906

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160926

R150 Certificate of patent or registration of utility model

Ref document number: 6014596

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees